Treatment with PRMT5 inhibitor EPZ015666 resulted in decreased MYC protein levels and medulloblastoma cell growth, indicating that PRMT5 inhibitors are potential treatments for MYCN-driven cancer [218]. This evidence concerns the gene MYC and cancer.